Clinical trial
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With…
NCT02573324 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT02573324 |
|---|---|
| Title | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification |
| Official title | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) |
| Acronym | Intellance1 |
| Lead sponsor | AbbVie, Industry |
| Collaborators | Radiation Therapy Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma, Gliosarcoma |
| Intervention type | Drug, Radiation |
| Interventions | Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414 |
| Enrollment | 691 |
| Start date | Jan 4, 2015 |
| Primary completion | Apr 4, 2022 |
| Completion | Apr 4, 2022 |
| First posted | Oct 9, 2015 |
| Last update posted | May 11, 2023 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong and 16 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: